TREATMENT OF CANCER USING A SMAD3 INHIBITOR

The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-β signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration...

Full description

Saved in:
Bibliographic Details
Main Author LAN, Hui Yao
Format Patent
LanguageEnglish
French
German
Published 21.08.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-β signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration of SIS3, an inhibitor of Smad3. Further provided are compositions and kits useful for treating cancer by way of inhibiting Smad3 signaling.
Bibliography:Application Number: EP20190150641